The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CDNA | -37.01% | -70.95% | -21.91% | +52% |
| S&P | +15.06% | +95.03% | +14.29% | +240% |
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
The company's diagnostic tests may obtain better coverage from the Centers for Medicare & Medicaid Services.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $86.68M | -6.1% |
| Gross Profit | $57.37M | -9.9% |
| Gross Margin | 66.19% | -2.8% |
| Market Cap | $1.09B | 34.5% |
| Market Cap / Employee | $1.67M | 0.0% |
| Employees | 650 | 1.1% |
| Net Income | -$8.57M | -514.6% |
| EBITDA | -$6.12M | -759.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $68.21M | -28.8% |
| Accounts Receivable | $67.36M | 1.8% |
| Inventory | 27.9 | 45.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $22.78M | -10.3% |
| Short Term Debt | $6.34M | 4.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 13.47% | 46.0% |
| Return On Invested Capital | -16.36% | 7.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $8.89M | -48.2% |
| Operating Free Cash Flow | $9.90M | -47.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 21.05 | 15.41 | 19.14 | - | |
| Price to Book | 6.07 | 4.16 | 2.57 | 2.86 | -8.98% |
| Price to Sales | 5.28 | 3.73 | 2.83 | 3.11 | 14.10% |
| Price to Tangible Book Value | 8.61 | 5.91 | 3.24 | 3.59 | -22.94% |
| Price to Free Cash Flow TTM | 1351.81 | 39.49 | 48.68 | 89.33 | - |
| Enterprise Value to EBITDA | -257.19 | -238.08 | -253.83 | -147.81 | -122.35% |
| Free Cash Flow Yield | 0.1% | 2.5% | 2.1% | 1.1% | - |
| Return on Equity | -43.0% | 19.5% | 21.6% | 20.7% | -143.50% |
| Total Debt | $29.97M | $28.37M | $30.28M | $29.12M | -7.40% |
CDNA earnings call for the period ending September 30, 2021.
CDNA earnings call for the period ending June 30, 2021.
CDNA earnings call for the period ending March 31, 2021.
CDNA earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
